Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Non-alcoholic steatohepatitis, the more severe form of non-alcoholic fatty liver disease, is highly prevalent in the HIV population.
A recent study found one in five people with HIV should be assessed for fatty liver, and 1 in 10 should be referred to a liver specialist.
Gastrointestinal cancers conference emphasizes patient quality of life.
Researchers call for greater use of noninvasive measures of fatty liver disease in this population to identify those at risk.
About a quarter of people taking a higher dose of Ocaliva saw an improvement in liver fibrosis.
The 2019 Liver Meeting in Boston provided an array of important findings about the treatment and prevention of chronic liver diseases.
This could provide a safer, simpler alternative to the invasive surgical biopsies used to diagnosis liver disease.
The injectable hormone was approved to treat excess abdominal fat in those with antiretroviral-associated lipodystrophy.
The application is based on study results showing that up to 23% of treated patients saw an improvement in liver fibrosis.
Currently, there are no pharmacological treatments for liver fibrosis related to non-alcoholic steatohepatitis.
Study finds people who took daily aspirin had a lower risk of NASH and advanced liver scarring.
The number of HIV-positive Medicare recipients with liver disease is rising, almost entirely as a result of NAFLD
In an analysis of the liver health of a cohort of HIV/hep B–coinfected people, one third had significant fibrosis.
Among people with HIV who don’t have hepatitis C virus, various factors raise the risk of liver fibrosis and fatty liver disease.
Metabolic disorders are linked to liver scarring and fat accumulation in HIV-positive people.
Highlights from research presented at the 52nd International Liver Congress in Amsterdam
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.